Shionogi & Co. Ltd.
History
| Year | Detail |
|---|---|
| 1878 | Gisaburo, the company's founder, launched his drug wholesaler, Shiono Gisaburo Shoten, in Doshomachi 3-chome 12, Osaka. |
| 1909 | The company shifted its focus from manufacturing Western medicines to developing new drugs. This marked a significant transition for the company. The first drug developed during this era was Antacidin, an antacid used to treat stomach conditions. |
| 1919 | Shionogi Shoten was established as a merger of Shiono Gisaburo Shoten, the drug wholesaler supervised by Gisaburo’s eldest son, Shotaro, and Shiono Seiyakusho, the pharmaceutical business managed by Chojiro. |
| 1943 | The corporate name was changed to Shionogi & Co., Ltd. (Shionogi Pharmaceuticals in English) to demonstrate that the business would focus on pharmaceutical activities. |
| 1953 | Shionogi launched Popon-S, a multivitamin supplement, in 1953. The name “Popon-S” combines “Popon,” a lively onomatopoeia meaning “extraordinary vigorous vitality and eagerness,” and “S” for “Shionogi.” |
| 1959 | The company launched Sinomin, the first sulfonamide antibiotic drug discovered and developed by Shionogi. |
| 1961 | A basic research facility, Shionogi Research Laboratories (now integrated into Shionogi Pharmaceutical Research Center), was established to conduct antibiotic research. |
| 1982 | Shionogi Research Laboratories successfully discovered and launched an in-house product: Shiomarin, the world's first oxacephem antibiotic. |
| 1983 | The company established the Kanegasaki Plant, one of Shionogi’s key plants, in Kanegasaki-cho, Isawa-gun, Iwate, to expand pharmaceutical plant facilities in the future. |
| 2001 | The company established a joint venture with GlaxoSmithKline, a U.K.-based pharmaceutical company. This partnership resulted in an improved management culture and steady progress in developing pipelines (candidate compounds under development). |
| 2003 | Shionogi launched Crestor (rosuvastatin calcium), a hyperlipidemia treatment licensed to the UK-based pharmaceutical company AstraZeneca. It became a globally significant drug for high cholesterol and related conditions. |
| 2008 | The company acquired U.S.-based Sciele Pharma, Inc., for a firm value of $1.4 billion to streamline overseas sales for products discovered in-house. |
| 2011 | The company acquired C&O Pharmaceutical Technology (Holdings) Limited (C&O), a Chinese pharmaceutical manufacturer listed on the Singapore Stock Exchange, to strengthen its presence in the rapidly growing Chinese market. |
| 2016 | Shionogi entered into a collaboration agreement with Nissan Chemical Industries, Ltd. The collaboration focused on addressing the need for innovative treatments in antifungal therapy, particularly treating infections caused by resistant fungal strains. |
| 2016 | The company collaborated with PeptiDream Inc., a biopharmaceutical company specializing in peptide-based drug discovery. The collaboration aimed to explore these peptides to address challenging drug targets and medical needs. |
| 2018 | The company established a new manufacturing subsidiary in Japan to enhance its production capabilities, strengthen its manufacturing infrastructure, and support the production of pharmaceutical products. |
| 2018 | The company collaborated with TetraDiscovery Partners on the development and commercialization of BPN14770, a therapeutic candidate for treating central nervous system disorders such as Alzheimer's disease and Fragile X syndrome. |
| 2019 | Akili Interactive, a digital medicine company creating prescription treatments for people living with cognitive dysfunction and brain-related conditions, and Shionogi partnered to develop and commercialize digital therapeutics in key Asian markets. |
| 2019 | M3 Inc., a provider of medical information services, entered a joint venture with the company to address healthcare needs through innovative disease solutions. Together, they established a new company called Stream-I, Inc. |
| 2020 | The company entered partnerships with Nihon University, Gunma University, and Tokyo Medical University to develop rapid diagnostic methods for viruses in infectious diseases, including novel coronaviruses. |
| 2021 | Shimadzu Corp. and Shionogi established the joint venture AdvanSentinel Inc., which is focused on public health risk assessment, including wastewater surveillance. |
| 2021 | Shionogi & Co., Ltd and NEC Corp collaborated on the development of a novel hepatitis B therapeutic vaccine. |
| 2022 | Shionogi & Co., Ltd. and F2G Ltd., to develop and commercialize the new antifungal agent olorofim for invasive fungal infections in Europe and Asia. |
| 2023 | The company formed a joint venture with Accenture Co., Ltd. to accelerate business reforms further and enhance employees' expertise. Shionogi Pharmacovigilance Center Co., Ltd. was absorbed into Shionogi Business Partner on July 1, 2023, to synergize with Accenture's business process-managed services related to safety management operations. |
| 2023 | Swedish Orphan Biovitrum AB signed a distribution agreement for Shionogi's Fetcroja product in Bulgaria, Croatia, Czech Republic, Hungary, Poland, Romania, Slovakia, Cyprus, Estonia, Greece, Latvia, and Lithuania. |
| 2024 | The company partnered with FRONTEO, Inc., to collaboratively develop high-performance diagnostic support AI models and medical and non-medical devices to enhance the efficiency of diagnosing mental and neurological disorders. |
BCC Research Beacon 